| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2402118 | Tuberculosis | 2007 | 4 Pages |
SummaryNovel anti-HIV agents that target different stages of the human immunodeficiency virus type 1 (HIV-1) replication cycle are now in clinical trials and have signs of improving our ability to manage HIV-1. This chapter, and the Conference presentation, dealt with the challenges encountered in realizing the optimal benefits of the newer therapeutics to individuals with AIDS and HIV-1 infection receiving highly active antiretroviral therapy (HAART). Emphasis was on the G-protein-coupled seven-transmembrane chemokine receptor, CCR5, as a potentially new therapeutic target and experience with novel CCR5 inhibitors, and the promise from further advancement through structural and molecular analysis of CCR5 inhibitor–CCR5 interactions. The promise in some of the newer protease inhibitors was also discussed.
